Japan Weekly Strategy Report – Nikkei Average within range of 23,000 Yen May 21, 2018 1696

Japanese stocks had risen sharply in April and continued to be strong in May.  As 5/17, the monthly rate of increase was 1.65% for the Nikkei Average and 1.75% for TOPIX.  NY Dow rose by 2.28% led by the appreciation of APPLE (APPL).  The SOX index consisting of 30 semiconductor stocks increased by 9.68%.  Domestically, some semiconductor stocks have been rising sharply, but we believe that there is still room for further study mainly of high-tech stocks.

The dollar/yen exchange rate was 113 yen to the dollar at the beginning of the year.  Since then, the dollar had depreciated with the exchange rate temporarily at 104 yen to the dollar on 3/26, resulting in yen appreciation.  The Nikkei Average, which attained a post-bubble recovery high of 24,000 yen in January, dropped sharply to 20,300 yen temporarily on 3/26.  However, after that, the dollar/yen situation reversed with the dollar appreciating.  Currently, yen has weakened more than 6 yen to reach 111 yen.  This yen depreciation has pushed the market upwards, with the Nikkei Average closing price reaching 22,838.37 yen on 5/17, within range of 23,000 yen.  In fact, the Nikkei Average has risen 10.8% from the low of 20,617.86 yen on 3/23 recorded for the first part of the year.

However, Applied Materials (AMAT), the world’s largest semiconductor device manufacturer, released its results on 5/17, and announced a 2018/10 3Q (May-July) sales plan which is lower than market expectations.  Its stock price subsequently declined sharply temporarily in after-hours trading.    We therefore need to pay attention to US stock movements especially for high-tech stocks in the short term.  Furthermore, we need to discern China’s response to US demands during the second round of the US-China trade talks, as we expect the results to impact market situation.  We therefore need to closely track these developments.  With regards the upcoming US-North Korea summit, it seems that negotiations on conditions for the complete denuclearization of North Korea are progressing behind the scenes, and we can expect many twists and turns going forward.  Withdrawal of the US from the Iran nuclear agreement is also expected to impact Europe.  Under such situations, we need to pay attention to the foreign policy and rate of increase of interest rate of the US, and their potential impact on the stock market.

Meanwhile, US economic indicators continue to be favorable, and additional interest rate increase is expected at the June FOMC.  The dollar is expected to rise further against the yen.  Domestic listed companies which had been adopting a cautious stance are expected to revise their 2019/3 forecast upwards.  We expect the Nikkei Average to rise further in view of the forecasted currently 13-fold PER level. 

In the 5/21 issue, we will be covering Mitsui Chemicals (4183),   Terumo Corp (4543), Idemitsu Kosan (5019), Sagami Rubber Industries (5194), Tokyo Seimitsu (7729) and Yamato Holdings (9064).

 

Selected Stocks

Mitsui Chemicals, Inc. (4183)

・Comprehensive chemical manufacturer established in 1997.  Deals with “mobility” products centred on automobile materials, “healthcare” products such as spectacle lens materials, dental materials, non-woven fabrics, “food and packaging” products such as agricultural chemicals, packaging materials, and “basic materials” including petrochemicals and basic chemicals.  Has a global share of 45% for plastic spectacle lens materials.

・For FY2018/3, net sales increased by 9.6% to 1.3285 trillion yen compared to the same period the previous year,  operating income increased by 1.3% to 103.491 billion yen, and net income increased by 10.4% to 71.585 billion yen.  Petrochemical products continue to enjoy strong domestic demand, with facility operations such as naphtha crackers operating at high levels.  High performance resins for automobiles and non-woven fabrics for disposable diapers also performed well.

・For FY2019/3 plan, net sales is expected to increase by 11.4% to 1.48 trillion yen compared to the previous year, operating income to increase by 2.4% to 106 billion yen, and net income to increase by 11.8% to 80 billion yen.  Besides the contribution from production capacity expansion of resin used for automobile bumpers etc, inquiries are also expected to increase for spectacle lens materials and non-woven fabrics.

Terumo Corporation (4543)

・Established in 1921. Manufactures and sells pharmaceuticals and medical devices both in Japan and overseas.  Apart from pharmaceuticals, also manufactures and sells nutritional foods, blood transfusion devices, disposable medical devices, artificial organs and electronic thermometers. 

・For FY2018/3, net sales increased by 14.3% to 587.775 billion yen compared to the same period the previous year,  operating income increased by 23.7% to 108.552 billion yen, and net income increased by 66.0% to 91.295 billion yen.  Achieved highest profit on record.  Sales of access devices, ultrasound imaging diagnostic apparatus “VISICUBE”, intravascular ultrasound catheter “AltaView” etc were strong. 

・For FY2019/3 plan, net sales is expected to increase by 3.4% to 608 billion yen compared to the previous year, operating income to increase by 5.5% to 114.5 billion yen, and net income to decrease by 8.5% to 83.5 billion yen.  Although catheters are expected to perform well, tax expenses temporarily decreased in the previous term due to tax cuts in its US entities.  Medical Excellence Japan, which comprises 50 companies including this company, will be working with the government to export medical infrastructure to India.

Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE

Where the report contains research analyses or reports from a foreign research house, please note:

  1. recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
  2. to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.

Get access to all the latest market news, reports, technical analysis
by signing up for a free account today!